Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term aspirin therapy and susceptibility to SARS-CoV-2 infection in aspirin-exacerbated respiratory disease
2021-003897-30Phase 2Active
- Sponsor
- Jagiellonian University Medical College
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aspirin in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD) and asthma, sponsored by Jagiellonian University Medical College. Started Mar 2022; status: active.
02
Drugs
aspirin
03
Conditions
nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD)asthma
Beyond the preview
Go deeper on 2021-003897-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003897-30.